Abstract: Arrangements of the innovation relate to a micro-coring system configured to harvest a plurality of cores, either sequentially or simultaneously. In one arrangement, the micro-coring system comprises a harvesting tool configured to harvest and transfer at least one tissue core from a donor site to a recipient site, the at least one tissue core having a diameter of between about 1.0 mm and 3.0 mm diameter. In one arrangement, the harvesting tool comprises: a coring tool configured to penetrate tissue at the donor site and capture a tissue core from the tissue, and an extractor pin disposed within an aperture extending along a longitudinal axis of the coring tool, the extractor pin configured to extract the core from the coring tool.

Abstract: An article is configured for transferring tissue cores from a patient donor site to a patient wound site. The article includes a matrix construction of resilient elastomeric polymer material to support an array of tissue core locators individually defining an opening and individually configured to: (1) receive a tissue core from the donor site into the opening, (2) resiliently hold the tissue core at the opening until and after the sheet is placed upon the wound site, and (3) release the tissue core when the sheet is removed from the wound site at a time that is between 2 and 29 days after the sheet is placed upon the wound site.

Abstract: Systems and methods for assembling a plurality of tissue grafts are provided. A system includes a pick and place unit, a transfer tool, and a control unit. The pick and place unit includes a moveable arm and the transfer tool is coupled to a distal end of the arm. The control unit is configured to control the moveable arm to move the transfer tool to a donor site and a graft construction site. The control unit is further configured to control the transfer tool to harvest the micro tissue grafts from the donor site and arrange the micro tissue grafts into a supportive matrix to form a custom graft.

Abstract: The present disclosure relates to a computer-implemented method for processing data in one or more data processing devices to determine a likelihood score or the probability of immune-related adverse events associated with immunotherapy.

Abstract: A method is provided in various embodiments for determining a profile data set for a subject with colorectal cancer or conditions related to colorectal cancer based on a sample from the subject, wherein the sample provides a source of RNAs. The method includes using amplification for measuring the amount of RNA corresponding to at least 1 constituent from Tables 1-5. The profile data set comprises the measure of each constituent, and amplification is performed under measurement conditions that are substantially repeatable.

Abstract: A method is provided in various embodiments for determining a profile data set for predicting the survivability of a subject with prostate cancer based on a sample from the subject, wherein the sample provides a source of RNAs. The method includes using amplification under measurement conditions that are substantially repeatable for measuring the amount of RNA corresponding to at least 1 constituent from Table 1. Alternatively, the method uses electrophoresis or immunohistochemistry for measuring the mount of protein corresponding to at least 1 constituent from Table 20. The profile data set comprises the measure of each constituent.

Abstract: A method is provided in various embodiments for determining a profile data set for a subject with osteoarthritis or conditions related to osteoarthritis based on a sample from the subject, wherein the sample provides a source of RNAs. The method includes using amplification for measuring the amount of RNA corresponding to at least one constituent from Tables 1-2, 4-6, and 8. The profile data set comprises the measure of each constituent, and amplification is performed under measurement conditions that are substantially repeatable.

Abstract: A method is provided in various embodiments for determining a profile data set for a subject with rheumatoid arthritis or inflammatory conditions related to rheumatoid arthritis based on a sample from the subject, wherein the sample provides a source of RNAs. The method includes using amplification for measuring the amount of RNA corresponding to at least 2 constituents from Tables 1-2 and Tables 4-10. The profile data set comprises the measure of each constituent, and amplification is performed under measurement conditions that are substantially repeatable.

Abstract: Rodent gene expression data, in particular, gene expression profiles, are created and used to predict the efficacy of therapeutic agents on human biological conditions. Gene Profile data sets are derived from rodent subject samples and include quantitative, substantially repeatable measures of a distinct amount of RNA or protein constituent(s) in a signature panel selected such that measurement of the constituent(s) enables measurement of a biological condition of interest in both human and rodent subjects. Such profile data sets may be used to predict the therapeutic efficacy of a therapeutic agent in humans.

Abstract: A method is provided in various embodiments for determining a profile data set for predicting the response top immunotherapy and or survivability of a subject with melanoma based on a sample from the subject, wherein the sample provides a source of RNAs. The method includes using amplification under measurement conditions that are substantially repeatable for measuring the amount of RNA corresponding to at least 2, 3 or 4 constituents according to the gene models shown in Tables 2-3, 4-6 and 9.

Abstract: A method is provided in various embodiments for determining a profile data set for a subject with cervical cancer or conditions related to cervical cancer based on a sample from the subject, wherein the sample provides a source of RNAs. The method includes using amplification for measuring the amount of RNA corresponding to at least 1 constituent from Tables 1-5. The profile data set comprises the measure of each constituent, and amplification is performed under measurement conditions that are substantially repeatable.

Abstract: A method is provided in various embodiments for determining a profile data set for a subject with breast cancer or conditions related to breast cancer based on a sample from the subject, wherein the sample provides a source of RNAs. The method includes using amplification for measuring the amount of RNA corresponding to at least 1 constituent from Tables 1-5. The profile data set comprises the measure of each constituent, and amplification is performed under measurement conditions that are substantially repeatable.

Abstract: A method is provided in various embodiments for determining a profile data set for a subject with skin cancer or a condition related to skin cancer based on a sample from the subject, wherein the sample provides a source of RNAs. The method includes using amplification for measuring the amount of RNA corresponding to at least 1 constituent from Tables 1-6. The profile data set comprises the measure of each constituent, and amplification is performed under measurement conditions that are substantially repeatable.

Abstract: A method is provided in various embodiments for determining a profile data set for a subject with prostate cancer or conditions related to prostate cancer based on a sample from the subject, wherein the sample provides a source of RNAs. The method includes using amplification for measuring the amount of RNA corresponding to at least 1 constituent from Tables 1-4. The profile data set comprises the measure of each constituent, and amplification is performed under measurement conditions that are substantially repeatable.

Abstract: A method is provided in various embodiments for determining a profile data set for a subject with ovarian cancer or conditions related to ovarian cancer based on a sample from the subject, wherein the sample provides a source of RNAs. The method includes using amplification for measuring the amount of RNA corresponding to at least 1 constituent from Tables 1-5. The profile data set comprises the measure of each constituent, and amplification is performed under measurement conditions that are substantially repeatable.

Abstract: A method is provided in various embodiments for determining a profile data set for a subject with ocular disease or conditions related to ocular disease based on a sample from the subject, wherein the sample provides a source of RNAs. The method includes using amplification for measuring the amount of RNA corresponding to at least one constituent from Tables 1-5, 7-9, and 11-13. The profile data set comprises the measure of each constituent, and amplification is performed under measurement conditions that are substantially repeatable.

Abstract: A method is provided in various embodiments for determining a profile data set for a subject with colorectal cancer or conditions related to colorectal cancer based on a sample from the subject, wherein the sample provides a source of RNAs. The method includes using amplification for measuring the amount of RNA corresponding to at least 1 constituent from Tables 1-5. The profile data set comprises the measure of each constituent, and amplification is performed under measurement conditions that are substantially repeatable.

Abstract: A method is provided in various embodiments for determining a profile data set for a subject with lung cancer or conditions related to lung cancer based on a sample from the subject, wherein the sample provides a source of RNAs. The method includes using amplification for measuring the amount of RNA corresponding to at least 1 constituent from Tables 1-5. The profile data set comprises the measure of each constituent, and amplification is performed under measurement conditions that arc substantially repeatable.

Abstract: Rodent gene expression data, in particular, gene expression profiles, are created and used to predict the efficacy of therapeutic agents on human biological conditions. Gene Profile data sets are derived from rodent subject samples and include quantitative, substantially repeatable measures of a distinct amount of RNA or protein constituent(s) in a signature panel selected such that measurement of the constituent(s) enables measurement of a biological condition of interest in both human and rodent subjects. Such profile data sets may be used to predict the therapeutic efficacy of a therapeutic agent in humans.

Abstract: The present invention provides methods of characterizing multiple sclerosis or inflammatory conditions associated with multiple sclerosis using gene expression profiling.